Related Experiment Video
Updated: Jun 4, 2025
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers
Minggui Pan1, Maggie Zhou2, Lu Xie3
1Department of Medicine Division of Oncology, Sarcoma Program, Stanford University School of Medicine, Stanford, Palo Alto, CA, 94305, USA. minggui@stanford.edu.
Abstract:
Soft tissue and bone sarcomas are a heterogenous group of uncommon mesenchymal tumors with high unmet needs for novel therapeutic and diagnostic strategies. Despite many challenges that persist, innovative therapeutics are emerging. Here we provide a review of the studies presented at the 2024 American Society of Clinical Oncology annual meeting that were focused on sarcoma. There were many outstanding studies that were reported at the meeting. We begin by discussing the clinical studies on soft tissue sarcoma (STS) that included multiple histology subtypes, followed by highlighting developments in cellular therapy, before delving into specific STS histologic subtypes followed by a section covering the studies that were focused on predictive biomarkers. We conclude by discussing the studies in bone sarcomas. Some of the studies discussed here are likely to be practice changing. Some of the early-phase clinical trials have shown encouraging results.
Insights
Innovative therapies for soft tissue and bone sarcomas are emerging. This review covers key findings from the 2024 American Society of Clinical Oncology meeting, highlighting new treatments and biomarkers.
Area of Science:
- Oncology
- Sarcoma Research
- Clinical Trials
Background:
- Soft tissue and bone sarcomas are rare mesenchymal tumors with significant unmet needs.
- Current therapeutic and diagnostic strategies face challenges, necessitating innovation.
Purpose of the Study:
- To review studies on sarcoma presented at the 2024 American Society of Clinical Oncology annual meeting.
- To highlight emerging therapeutic and diagnostic strategies for sarcomas.
Main Methods:
- Review of clinical studies presented at the 2024 American Society of Clinical Oncology meeting.
- Categorization of studies by sarcoma type (soft tissue, bone), cellular therapy, and predictive biomarkers.
Main Results:
- Outstanding studies were reported across various sarcoma subtypes.
- Early-phase clinical trials show encouraging results for novel treatments.
- Developments in cellular therapy and predictive biomarkers were presented.
Conclusions:
- Emerging innovative therapeutics offer new hope for sarcoma patients.
- Some discussed studies are anticipated to be practice-changing.
- Continued research and clinical trials are crucial for advancing sarcoma care.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
01:21Cancer Survival Analysis